Company intelligence / Profile preview

Satipharm

Ownership: Private
Development stage: Other

Overview

Satipharm’s Advanced CBD capsules have demonstrated significant efficacy over standard CBD oils in clinical trials, including a successful Phase 2 trial in refractory epilepsy. A Phase 3 trial is ongoing for sleep disturbances. The company’s patented Gelpell® microbead delivery system improves stability and bioavailability of oral cannabinoids

Therapeutic areas: Neurology
Modalities: Small molecule (cannabidiol/CBD)Plant extract (hemp-derived cannabinoids)Microbead drug delivery technology (Gelpell®)
Industry: Biotech

Drug pipeline

1 asset

Sativol

Unknown

Partnerships

GSK Consumer Healthcare

Beyond the preview

Go deeper on Satipharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Satipharm.